Semaglutide vs exenatide: evidence, cost, and legality

Which is better, semaglutide or exenatide?

Semaglutide wins on direct randomized evidence (SUSTAIN 3), on cardiovascular outcomes (SUSTAIN-6 hazard ratio 0.74 and SELECT hazard ratio 0.80 versus EXSCEL hazard ratio 0.91, not superior to placebo), and on label breadth, since it is also approved for weight management. Both are FDA approved and both carry the human_rct evidence grade, so the difference is effect size and outcomes, not legitimacy. Exenatide mainly makes sense when a formulary or prior response favors it. [1] [2] [3] [4] [5] [7]

How do semaglutide and exenatide compare?

Semaglutide and Exenatide compared by dimension
Dimension	SemaglutideFavored	Exenatide
Head-to-head evidence [1]	SUSTAIN 3 (813 adults with type 2 diabetes, 56 weeks): semaglutide 1 mg weekly lowered HbA1c by 1.5 points and weight by 5.6 kg; 67% reached HbA1c below 7%.	Exenatide extended release 2 mg weekly lowered HbA1c by 0.9 points and weight by 1.9 kg; 40% reached HbA1c below 7%.
Note: Open label randomized trial; estimated treatment difference minus 0.62 HbA1c points and minus 3.78 kg in favor of semaglutide.
Molecule and mechanism [5] [6] [7]	Acylated analog of human GLP-1 that binds albumin, half life about one week.	Synthetic exendin-4 from Gila monster saliva, about 53% identical to human GLP-1; the immediate release form has a half life of about 2.4 hours and the weekly form uses microspheres.
Note: Both activate the same GLP-1 receptor; the difference is potency and duration of exposure.
Cardiovascular outcomes [2] [3] [4]	SUSTAIN-6 (3,297 adults with type 2 diabetes): hazard ratio 0.74 for major adverse cardiovascular events. SELECT (17,604 adults with obesity and cardiovascular disease, no diabetes): hazard ratio 0.80.	EXSCEL (14,752 adults with type 2 diabetes): 11.4% versus 12.2% major adverse cardiovascular events, hazard ratio 0.91 (95% CI 0.83 to 1.00); noninferior but not superior to placebo.
FDA labeled indications [5] [6] [7]	Ozempic and Rybelsus for type 2 diabetes (Ozempic also for cardiovascular and kidney risk reduction in type 2 diabetes); Wegovy for chronic weight management, cardiovascular risk reduction in obesity, and MASH.	Byetta and Bydureon BCise for type 2 diabetes only; Bydureon BCise is also labeled for children 10 and older. No weight management indication.
Route and dosing frequency [5] [6] [7]	Subcutaneous injection once weekly, or an oral tablet once daily (Rybelsus).	Subcutaneous injection twice daily before meals (Byetta, 5 then 10 ug) or once weekly (Bydureon BCise, 2 mg).
Side effects that differ [1] [5] [7]	More gastrointestinal adverse events in SUSTAIN 3 (41.8%) but very few injection site reactions (1.2%).	Fewer gastrointestinal events in SUSTAIN 3 (33.3%) but far more injection site reactions (22.0%), including microsphere nodules; anti-exenatide antibodies develop in a substantial minority.
Note: Both carry nausea, vomiting, and diarrhea during escalation, and both weekly forms carry the thyroid C-cell tumor boxed warning.
Regulatory and compounding status [6] [7] [8]	FDA approved (2017 to 2021 products). Shortage ended February 21, 2025; routine compounding had to stop by April 22 (503A) and May 22, 2025 (503B).	FDA approved (Byetta 2005, Bydureon 2012, Bydureon BCise 2017). Never in shortage; compounding limited to documented patient specific need.
Typical cost [7] [9]	Ozempic list about 998 USD and Wegovy about 1,349 USD per month; manufacturer cash pricing for Wegovy roughly 349 to 499 USD per month.	Byetta and Bydureon BCise list roughly 800 to 1,000 USD per month; often 25 to 100 USD with commercial coverage. No generic.
Note: Prices at the verification date change often; see the cost pages.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Semaglutide and Exenatide: grade, status, and cost
Attribute	Semaglutide	Exenatide
Class	GLP-1 receptor agonist (31 amino acid analog of human GLP-1, acylated for once weekly dosing)	GLP-1 receptor agonist (synthetic 39 amino acid exendin-4, originally isolated from Gila monster saliva; twice daily and once weekly extended release forms)
What it is	FDA approved GLP-1 agonist with about 15% average weight loss in a 68 week RCT and proven cardiovascular benefit.	The first GLP-1 drug, FDA approved in 2005; lowers HbA1c (3 month blood sugar) 0.8 to 1.9 points with 2 to 4 kg weight loss; no proven heart benefit.
Evidence	Evidence: Human RCT evidence	Evidence: Human RCT evidence
FDA status	Regulatory: FDA approved	Regulatory: FDA approved
Compounding	FDA approved products (Ozempic 2017, Rybelsus 2019, Wegovy 2021). FDA removed semaglutide from the drug shortage list on February 21, 2025; compounding by 503A pharmacies had to stop by April 22, 2025 and by 503B outsourcing facilities by May 22, 2025, except for a documented patient specific clinical need. FDA has warned about unapproved compounded and counterfeit GLP-1 products and salt forms (semaglutide sodium, semaglutide acetate) that are not the approved active ingredient. On April 30, 2026 FDA proposed not to include semaglutide on the 503B bulks list; that proposal was not final as of September 2026. Adding a vitamin such as B12 or niacinamide does not by itself make a compounded GLP-1 different from the approved drug. Under FDA's April 1, 2026 policy update, such a combination may be treated as essentially a copy when the strengths are within 10% of approved products and the route is the same, unless a prescriber documents a real difference for the individual patient. A September 2026 FDA warning letter applied this to semaglutide and tirzepatide vitamin combinations, said high production volume suggested the claimed differences were a pretext, and questioned significant-difference statements picked from preset menus on prescribing platforms.	FDA approved products (Byetta April 2005, Bydureon January 2012, Bydureon BCise October 2017) for type 2 diabetes. Because exenatide is a component of approved drugs, 503A pharmacies may compound it only for a documented patient specific need and may not produce essentially a copy of a marketed product. Exenatide was not part of the semaglutide and tirzepatide shortage era. Product presentations have narrowed over time; check DailyMed for what is currently marketed.
WADA	WADA: Not WADA prohibited	WADA: Not WADA prohibited
Routes	Subcutaneous injection once weekly (Ozempic, Wegovy), Oral tablet once daily (Wegovy tablets, Ozempic tablets, Rybelsus)	Subcutaneous injection twice daily before meals (immediate release pen), Subcutaneous injection once weekly (extended release microsphere autoinjector)
Typical cost	Manufacturer list price is 1,349.02 USD per month for Wegovy and 1,027.51 USD for Ozempic (checked 2026-09-22), falling to 675 USD for both on January 1, 2027. Manufacturer self-pay prices run 149 to 499 USD per month by product and dose, with the Wegovy pen at 349 USD. With commercial insurance the manufacturer savings offer can bring a covered prescription to 25 USD per month, and eligible Medicare Part D enrollees pay 50 USD per month for Wegovy under the Medicare GLP-1 Bridge (July 2026 to December 2027). A 2024 study found compounded semaglutide at a median 231 USD for the first month during the shortage; compounding is now limited to patient specific needs.	Byetta and Bydureon BCise list at roughly 800 to 1,000 USD per month. With commercial insurance a covered prescription is often 25 to 100 USD per month, and Medicare Part D covers exenatide for type 2 diabetes. No generic is available as of the last verified date, and many formularies now prefer newer GLP-1 agonists.
Last verified	Sep 27, 2026	Sep 27, 2026

Has semaglutide been tested directly against exenatide?

Direct comparisons of Semaglutide and Exenatide
Study	Design and population	Outcome	Grade
Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial2018 PMID 29246950	Randomized, open label, active comparator trial, 56 weeksn = 813 Adults with type 2 diabetes on 1 to 2 oral glucose lowering drugs	HbA1c minus 1.5 versus minus 0.9 points and weight minus 5.6 versus minus 1.9 kg with semaglutide 1 mg versus exenatide ER 2 mg; injection site reactions 1.2% versus 22.0%	Evidence: Human RCT evidence

What do semaglutide and exenatide cost?

Typical cost of Semaglutide and Exenatide
Dimension	Semaglutide	Exenatide
Typical cost	$149 to $1,349 per month	Byetta and Bydureon BCise list at roughly 800 to 1,000 USD per month. With commercial insurance a covered prescription is often 25 to 100 USD per month, and Medicare Part D covers exenatide for type 2 diabetes. No generic is available as of the last verified date, and many formularies now prefer newer GLP-1 agonists.
Price detail	Semaglutide price by channel	Exenatide price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Is semaglutide stronger than exenatide?

Yes, on the direct evidence. In SUSTAIN 3, semaglutide 1 mg weekly lowered HbA1c by 1.5 points versus 0.9 for exenatide extended release 2 mg, and weight by 5.6 kg versus 1.9 kg over 56 weeks. [1]

Do both reduce heart attacks and strokes?

Semaglutide does: SUSTAIN-6 and SELECT both showed fewer major adverse cardiovascular events than placebo. Exenatide's EXSCEL trial showed it was safe for the heart but did not significantly reduce events (hazard ratio 0.91, 95% CI 0.83 to 1.00). [2] [3] [4]

Can exenatide be used for weight loss?

Not on label. Exenatide is approved only for type 2 diabetes, where it produces about 2 to 4 kg of weight loss. Semaglutide 2.4 mg (Wegovy) is approved for chronic weight management. [5] [6] [7]

Why would anyone still use exenatide?

Mainly formulary coverage, prior good response, or a preference for the twice daily Byetta pen that acts mostly on post meal glucose. It remains an FDA approved option with long safety follow-up, including the 14,752 person EXSCEL trial. [4] [6]

Are injection site reactions different?

Yes. In SUSTAIN 3, injection site reactions occurred in 22.0% of people on extended release exenatide versus 1.2% on semaglutide, largely because of the microsphere formulation, while gastrointestinal events were somewhat more common with semaglutide. [1]

Conditions studied

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 22). Semaglutide vs exenatide: evidence, cost, and legality. https://peptideagent.ai/compare/semaglutide-vs-exenatide
HTML link: <a href="https://peptideagent.ai/compare/semaglutide-vs-exenatide">Semaglutide vs exenatide: evidence, cost, and legality</a>, PeptideAgent, updated September 22, 2026.

Semaglutide vs exenatide

The short answer